治疗血管异常的医学疗法：第3部分。

IF 1.3 4区医学 Q3 DENTISTRY, ORAL SURGERY & MEDICINE

Oral and Maxillofacial Surgery Clinics of North America Pub Date : 2023-10-21 DOI:10.1016/j.coms.2023.09.013

Kiersten Ricci MD

引用次数: 0

摘要

遗传和体细胞遗传突变的发现，以及临床和科学研究的进步，提高了对血管异常的理解，并改变了治疗模式。为了最大限度地减少对侵入性手术的需求并改善疾病结果，分子靶向药物和抗血管生成剂作为外科手术的辅助药物，越来越成为血管异常的主要治疗药物。这篇文章强调了非恶性血管肿瘤和血管畸形的常用和新兴治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Medical Therapeutics for the Treatment of Vascular Anomalies

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oral and Maxillofacial Surgery Clinics of North America DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Published four times a year—February, May, August, and November—Oral and Maxillofacial Surgery Clinics of North America updates you on the latest trends in patient management and the newest advances, as well as provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in oral and maxillofacial surgery. Topics include reconstructive surgery, implants, dentoalveolar surgery, cleft and craniofacial surgery, craniomaxillofacial trauma surgery, TMJ, and cosmetic surgery.